LEMD1 Antibody | 6599

LEMD1 Antibody | 6599 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human, Mouse

Homology: N/A

Immunogen: LEMD1 antibody was raised against a 19 amino acid synthetic peptide near the center of human LEMD1.
The immunogen is located within amino acids 90 - 140 of LEMD1.

Research Area: Cancer, Cell Cycle

Tested Application: E, WB

Application: LEMD1 antibody can be used for detection of LEMD1 by Western blot at 1 μg/mL.
Antibody validated: Western Blot in mouse samples. All other applications and species not yet tested.

Specificiy: At least six isoforms of LEMD1 are known to exist; this antibody will detect the longest isoform. LEMD1 antibody is predicted to not cross-react with LEMD2 and LEMD3.

Positive Control 1: Cat. No. 1288 - A20 Cell Lysate

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: LEMD1 Antibody is affinity chromatography purified via peptide column.

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: LEMD1 Antibody is supplied in PBS containing 0.02% sodium azide.

Concentration: 1 mg/mL

Storage Condition: LEMD1 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: LEMD1 Antibody: CT50, LEMP-1, LEM domain-containing protein 1, LEM domain protein 1, CT50

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: LEMD1 Antibody: LEMD1 (LEM domain-containing1) is a member of cancer-testis gene family. LEMD1 is normally expressed only in testis. Six alternatively spliced forms of LEMD1 transcripts in normal testis have been identified, but only one of the six was expressed in colorectal cancers. LEMD1 may represent a promising target antigen for immunotherapy of colorectal cancers. In addition, LEMD1 and SPATA19 are putative cancer biomarkers and promising targets for active immunotherapy.